X4 Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| XFOR | CCCC | XNCR | XBRANE.ST | XBIT | CHRS | |
|---|---|---|---|---|---|---|
| Market cap | 321.24M | 383.84M | 2.60B | 266.84M | 59.45M | 131.36M |
| P/E (TTM) | 162.0 | — | — | — | — | — |
| Forward P/E | -4.2 | -3.4 | -9.9 | 647.5 | 15.0 | -1.3 |
| Price/book | 1.6 | 1.6 | 4.0 | 0.5 | 0.5 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −7.56% | +35.44% | +150.21% | +33.87% | −6.13% | −42.95% |
| Today | +2.21% | −2.80% | +14.33% | −3.36% | −2.01% | +5.54% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All XFOR news ›X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- 4WARD Phase 3 Chronic Neutropenia Trial Expected to Achieve Target Enrollment in Q4 2026 - - Initiating 4STEPS Phase 2b Trial Evaluating G-CSF Dose Reduction with Mavorixafor; Enrollment of First Participant Expected in Q1 2027 - -…
X4 Pharmaceuticals GAAP EPS of -$0.16 beats by $0.03
Read X4 Pharmaceuticals' Q3 earnings update: GAAP EPS of -$0.16 beat estimates by $0.03. - X4 Pharmaceuticals press release (XFOR): Q3 GAAP EPS of -$0.16 beats by $0.03. More on X4 Pharmaceuticals
X4 Pharmaceuticals (NASDAQ:XFOR) Posts Quarterly Earnings Results
Posted by Sarita Garza on Nov 4th, 2026 X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18)…
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day - Slideshow
2026-11-03. The following slide deck was published by X4 Pharmaceuticals, Inc. The following slide deck was published by X4 Pharmaceuticals, Inc. in conjunction with this event.
4DMT to Participate in Upcoming Investor Conferences
The Manila Times EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with…
Xtalks Announces its Life Science Webinar Calendar for November 2026
Nov 02, 2026, 08:00 ET TORONTO, Nov. 2, 2026 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and healthcare industries. Access to all webinars is…
X4 Pharmaceuticals (XFOR) Projected to Announce Earnings on Wednesday
Posted by Kim Johansen on Oct 28th, 2026 Shares of XFOR opened at $3.25 on Wednesday. X4 Pharmaceuticals has a 52-week low of $2.43 and a 52-week high of $4.83. The company has a 50-day simple moving average of $3.37 and a 200-day simple…
Xtremepush CEO Tommy Kearns to appear on Business Plus Talks
Xtremepush chief executive Tommy Kearns will guest on the next episode of Business Plus Talks, in association with Nostra. Every episode of Business Plus Talks features a business leader or entrepreneur who discusses the pivotal moments of…
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
New Taipei City, Taiwan/San Francisco, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech... Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow New…
Altrova Health to Host Investor Q&A Session on Tuesday, October 20 at 10:00 A.M. ET
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch RTX…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net7
- seekingalpha.com4
- manilatimes.net3
- theglobeandmail.com2
- abfjournal.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 26 articles, not a forecast.